Development of cGMP packaging cell lines for retro & lentivirus production using innovative molecular engineering strategies

点击翻译按钮获取中文摘要

Recent advances in the treatment of a range of autoimmune diseases and cancer have requiredincreasingly complex medical solutions. One rapidly expanding range of very successful treatments isthe delivery of DNA to human cells (gene therapy) to provide them with new features and propertiesto help fight disease. A highly efficient method of achieving this is to use modified viruses, such aslentiviruses, to deliver the DNA. However, the process of making lentiviruses is highly inefficientbecause no cells have yet been made that allow the virus to be packaged efficiently. The reason forthis is that some of the genes required to do this are toxic to the cell. We have recently developed anovel solution to this problem, and have already generated a first generation cell line that produceslentiviruses highly efficiently. We now aim to develop clinical grade versions of this cell line andcreate a series of further, more advanced, cell lines for improved lentivirus production.